MedTech Acquisition Corporation Announces Separate Trading of its Class A Common Stock and Warrants, Commencing February 8, 2021
MedTech Acquisition Corporation (Nasdaq:MTACU) announced that from February 8, 2021, holders of its 25 million initial public offering units can trade shares of Class A common stock and warrants separately on Nasdaq. The shares will trade under the symbols 'MTAC' for common stock and 'MTACW' for warrants, while the undivided units will continue trading as 'MTACU.' The registration statement for these securities was declared effective by the SEC on December 17, 2020. MedTech Acquisition aims to focus on merging with businesses in the medical technology sector.
- Holders can separate and trade shares of Class A common stock and warrants, increasing liquidity.
- The company targets the medical technology sector for potential mergers, suggesting a focused growth strategy.
- None.
New York, NY, Feb. 05, 2021 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (Nasdaq:MTACU) (the “Company”) announced today that, commencing February 8, 2021, holders of the 25,000,000 units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock and warrants included in the units. The shares of Class A common stock and warrants that are separated will trade on The Nasdaq Capital Market (“Nasdaq”) under the symbols “MTAC” and “MTACW”, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Those units not separated will continue to trade on Nasdaq under the symbol “MTACU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A common stock and warrants.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on December 17, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the units and the underlying securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, 1-800-248-8863, prospectus@raymondjames.com.
The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on businesses primarily operating in the medical technology sector in the United States. The Company is led by Chairman Karim Karti, Chief Executive Officer Christopher C. Dewey, Chief Financial Officer David J. Matlin, and Chief Administrative Officer Robert H. Weiss. In addition to Messrs. Karti, Dewey, and Matlin, the Company’s Board of Directors includes Maurice R. Ferré, Martin W. Roche, and Ivan Delevic. The Company’s special advisor is Michael Stansky.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and final prospectus for the initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
CONTACT
Christopher C. Dewey
MedTech Acquisition Corporation
(908) 391-1288
FAQ
When can I start trading MTAC and MTACW?
What is MedTech Acquisition Corporation's focus?
How many units are available for trading?
What is the significance of the effective registration statement on December 17, 2020?
